Quick Answer
SUTRO BIOPHARMA, INC. reported Total Assets of $173.83 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -55.1% in Total Assets from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $145.03 million | Q1 2019: $202.46 million | Q2 2019: $188.81 million | Q3 2019: $171.68 million | Q1 2020: $153.88 million | Q2 2020: $277.54 million | Q3 2020: $307.24 million | Q1 2021: $358.53 million | Q2 2021: $359.79 million | Q3 2021: $371.47 million | Q1 2022: $303.68 million | Q2 2022: $385.62 million | Q3 2022: $400.70 million | Q1 2023: $358.02 million | Q2 2023: $464.90 million | Q3 2023: $431.73 million | Q1 2024: $403.40 million | Q2 2024: $489.04 million | Q3 2024: $451.83 million | Q1 2025: $321.43 million | Q2 2025: $262.36 million | Q3 2025: $209.66 million.
- Over the full 9 years of available data (2017 to 2025), SUTRO BIOPHARMA, INC.'s Total Assets has grown by 326.4%.
- Historical annual values: Fiscal year 2025: $173.83 million | Fiscal year 2024: $387.21 million | Fiscal year 2023: $470.74 million | Fiscal year 2022: $406.94 million | Fiscal year 2021: $341.41 million | Fiscal year 2020: $394.11 million | Fiscal year 2019: $156.37 million | Fiscal year 2018: $223.14 million | Fiscal year 2017: $40.77 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: